Penserra Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Penserra Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,729	Closed	-$1.13M	–	1481
2021 Q4	$1.13M	Buy	11,729 +11,120	+1,826%	+$1.03M	0.02%	419
2021 Q3	$52K	Hold	609	–	–	﹤0.01%	1042
2021 Q2	$49K	Sell	609 -25,581	-98%	-$2.13M	﹤0.01%	1003
2021 Q1	$2.49M	Buy	26,190 +25,597	+4,317%	+$2.42M	0.05%	297
2020 Q4	$36K	Buy	593 +372	+168%	+$21.2K	﹤0.01%	744
2020 Q3	$13K	Buy	+221	New	+$15.1K	﹤0.01%	796
2018 Q4	–	Sell	-117,841	Closed	-$20.2M	–	719
2018 Q3	$20.2M	Buy	117,841 +4,522	+4%	+$682K	1.24%	21
2018 Q2	$14.6M	Buy	113,319 +44,624	+65%	+$4.98M	0.92%	38
2018 Q1	$7.08M	Buy	+68,695	New	+$6.79M	0.67%	54

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Penserra Capital Management's LGND Position: Q1 2022 in Review

Penserra Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2022, closing a stake of 11,729 shares — an estimated $1.13M sold.

Penserra Capital Management first reported a position in LGND in Q1 2018 and held it in 9 quarters. The position peaked at $20.2M in Q3 2018. 208 funds tracked by Wall St. Rank hold LGND as of Q1 2022.

Penserra Capital Management reported no remaining Ligand Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Penserra Capital Management sold 11,729 Ligand Pharmaceuticals shares in Q1 2022, an estimated $1.13M.
Penserra Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 9 quarters.
Penserra Capital Management's Ligand Pharmaceuticals position peaked at $20.2M in Q3 2018.
208 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2022.

Based on Penserra Capital Management's 13F filing for Q1 2022, filed 13 May 2022.